Effect of glucagon-(1-21)-peptide on secretin-stimulated pancreatic exocrine secretion in anesthetized dogs.
The effects of glucagon-(1-21)-peptide on pancreatic exocrine secretion and plasma glucose levels were studied and compared with those of native glucagon in anesthetized dogs. Intravenous bolus administration of 1 nmol or 10 nmol/kg of glucagon-(1-21)-peptide evoked a significant inhibition of secretin-stimulated pancreatic juice secretion and protein output in a dose-dependent manner, as equimolar doses of glucagon did. Native glucagon induced an immediate and transient increase in pancreatic juice volume, which was followed by a significant inhibition. However, glucagon-(1-21)-peptide showed only the inhibitory action. Glucagon-(1-21)-peptide had no effect on plasma glucose levels even when a dose of 10 nmol/kg was given. The results suggest that the N-terminal amino-acid residues of glucagon play an important role in the inhibition of pancreatic exocrine secretion.
Itoh
H
H
Second Department of Internal Medicine, Osaka University Medical School, Japan.
Matsuyama
T
T
Namba
M
M
Watanabe
N
N
Komatsu
R
R
Kono
N
N
Tarui
S
S
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D004285:Dogs; D005260:Female; D005934:Glucagon / Q000494:pharmacology*; D008297:Male; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism*; D010189:Pancreatic Juice / Q000187:drug effects / Q000378:metabolism*; D010446:Peptide Fragments / Q000494:pharmacology*; D011506:Proteins / Q000378:metabolism; D012633:Secretin / Q000494:pharmacology*
D001786:Blood Glucose; D010446:Peptide Fragments; D011506:Proteins; D012633:Secretin; C043386:glucagon (1-21); D005934:Glucagon